Emtricitabine with tenofovir alafenamide fumarate in HIV infection: additional benefits not covered

15 August 2016 - Deviation from the appropriate comparator therapy/higher loss for certain patients.

The combination of emtricitabine with tenofovir alafenamide fumarate is approved in combination with other anti-viral medicines to treat adults and young people with human immunodeficiency virus type 1 infection. In an early benefit assessment, the IQWiG has investigated whether this new combination product provides patients advantages over the appropriate comparator therapy.

An additional clinical benefit has not been established: for two of the four questions there are no data; the effects selected for the third question studies differ from the appropriate comparator therapy and for the fourth question, higher damage shows up for certain patients.

Read IQWiG press release [German]

Michael Wonder

Posted by:

Michael Wonder